July 10 (Reuters) - Australia has granted provisional approval to Gilead Sciences Inc 's GILD.O remdesivir as the first treatment option for COVID-19 in the country, the Therapeutic Goods Administration (TGA) said on Friday.
The approval is for adults and adolescent patients with severe COVID-19 symptoms and have been hospitalised, the Australian regulator said. (https:// has become the treatment of choice for many countries against severely ill COVID-19 patients after the intravenously-administered medicine helped shorten hospital recovery times in a clinical trial.
The Australian approval broadens the use of remdesivir around the world - the United States has cleared it for emergency use and the European Commission has conditionally approved the treatment.
It is also approved as a COVID-19 therapy in Japan, Taiwan, India, Singapore and the United Arab Emirates.
Australia has been struggling to contain a COVID-19 outbreak in the country's second most populous city and on Friday said it would halve the number of citizens allowed to return home from overseas each week. UPDATE 5-Australia restricts number of citizens returning as virus surges
UPDATE 2-Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance
FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19